Literature DB >> 25205472

Albuminuria is associated with elevated acute phase reactants and proinflammatory markers in HIV-infected patients receiving suppressive combination antiretroviral therapy.

Pichaya O-charoen1, Lishomwa C Ndhlovu, Louie Mar A Gangcuangco, Sheila M Keating, Philip J Norris, Roland C K Ng, Brooks I Mitchell, Cecilia M Shikuma, Dominic C Chow.   

Abstract

Albuminuria among HIV-infected individuals has been found to be associated with cardiovascular disease (CVD) and mortality. Inflammation has been associated with albuminuria. The pathophysiology of albuminuria in HIV-infected individuals is poorly understood. We investigated the association of albuminuria with inflammatory biomarkers among HIV-infected individuals on combination antiretroviral therapy (cART). This is a cross-sectional analysis of participants enrolled in the Hawaii Aging with HIV-Cardiovascular Cohort. Plasma inflammatory biomarkers were assessed using the Milliplex Human Cardiovascular disease multiplex assays. A random urine sample was collected for albumin measurement. Albuminuria was defined as urine albumin-to-creatinine ratio of ≥30 mg/g. Framingham risk score was calculated and divided into three classes. Simple and multivariable logistic regression analyses were utilized to assess the correlation between plasma inflammatory biomarkers and albuminuria and were adjusted for Framingham risk category. Among 111 HIV-infected patients [median (IQR) age of 52 (46-57) years, 86% male, median (IQR) CD4 count of 489 (341-638) cells/mm(3), 85% with HIV RNA <50 copies/ml], 18 subjects (16.2%) had moderately increased albuminuria (albuminuria range between 30 and 300 mg/g) and 2 subjects (1.8%) had severely increased albuminuria (albuminuria more than 300 mg/g). In multivariable logistic models, sE-selectin, sVCAM-1, CRP, SAA, and SAP remained significantly associated with albuminuria after adjustment of CVD risk factors. This study showed an association between inflammation and albuminuria independent of previously reported risk factors for albuminuria in HIV-infected subjects who were on combination antiretroviral therapy (cART). Chronic inflammation despite potent antiretroviral treatment may contribute to higher rates of albuminuria among HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25205472      PMCID: PMC4250959          DOI: 10.1089/AID.2014.0072

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  58 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples.

Authors:  S J Schwab; R L Christensen; K Dougherty; S Klahr
Journal:  Arch Intern Med       Date:  1987-05

3.  Use of single voided urine samples to estimate quantitative proteinuria.

Authors:  J M Ginsberg; B S Chang; R A Matarese; S Garella
Journal:  N Engl J Med       Date:  1983-12-22       Impact factor: 91.245

4.  Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study.

Authors:  A Festa; R D'Agostino; G Howard; L Mykkänen; R P Tracy; S M Haffner
Journal:  Kidney Int       Date:  2000-10       Impact factor: 10.612

5.  Urinary albumin excretion and its relationship to C-reactive protein and proinflammatory cytokines in patients with cancer and febrile neutropenia.

Authors:  Lars M Pedersen; Olav J Bergmann
Journal:  Scand J Infect Dis       Date:  2003

6.  Human serum amyloid A genes are expressed in monocyte/macrophage cell lines.

Authors:  S Urieli-Shoval; R L Meek; R H Hanson; N Eriksen; E P Benditt
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

7.  Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function.

Authors:  R L Meek; S Urieli-Shoval; E P Benditt
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

8.  Amyloid P-component in human glomerular basement membrane. Abnormal patterns of immunofluorescent staining in glomerular disease.

Authors:  R F Dyck; D J Evans; C M Lockwood; A J Rees; D Turner; M B Pepys
Journal:  Lancet       Date:  1980-09-20       Impact factor: 79.321

9.  Incidence of microalbuminuria in ambulatory patients with acquired immunodeficiency syndrome.

Authors:  D R Luke; T P Sarnoski; S Dennis
Journal:  Clin Nephrol       Date:  1992-08       Impact factor: 0.975

10.  Tumour necrosis factor-alpha and microalbuminuria in patients with inflammatory bowel disease.

Authors:  N Mahmud; M A O'Connell; J Stinson; M G Goggins; D G Weir; D Kelleher
Journal:  Eur J Gastroenterol Hepatol       Date:  1995-03       Impact factor: 2.566

View more
  3 in total

1.  Urinary albumin-to-creatinine ratio is associated with endothelial dysfunction in HIV-infected patients receiving antiretroviral therapy.

Authors:  Matteo Pirro; Massimo R Mannarino; Daniela Francisci; Elisabetta Schiaroli; Vanessa Bianconi; Francesco Bagaglia; Amirhossein Sahebkar; Elmo Mannarino; Franco Baldelli
Journal:  Sci Rep       Date:  2016-06-29       Impact factor: 4.379

2.  Associations between plasma tenofovir concentration and renal function markers in HIV-infected women.

Authors:  Mwila Mulubwa; Malie Rheeders; Carla Fourie; Michelle Viljoen
Journal:  South Afr J HIV Med       Date:  2016-07-28       Impact factor: 2.744

3.  Elevation of Non-Classical (CD14+/lowCD16++) Monocytes Is Associated with Increased Albuminuria and Urine TGF-β1 in HIV-Infected Individuals on Stable Antiretroviral Therapy.

Authors:  Brooks I Mitchell; Mary Margaret Byron; Roland C Ng; Dominic C Chow; Lishomwa C Ndhlovu; Cecilia M Shikuma
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.